A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

Prior treatment

• Received systemic anti-tumor therapies (including investigational agents) or major surgery within 4 weeks prior to the first study drug administration; palliative radiotherapy within 2 weeks or surgery within 4 weeks before study treatment initiation.
• History of hypersensitivity to monoclonal antibodies or any component of the investigational products to be administered in this study.
• History of thromboembolic disease within 6 months or hemoptysis within 3 months before first study medication. Subjects with muscular venous thrombosis not requiring anticoagulation per investigator's assessment are eligible for enrollment.
• Non-gastrointestinal bleeding within 6 months prior to first study drug administration, or active peptic ulcer disease.
• Unresolved toxicities and/or complications from prior interventions that have not recovered to baseline.
• Known or suspected interstitial lung disease (ILD); moderate-to-severe pulmonary disease significantly impairing respiratory function or autoimmune/connective tissue/inflammatory diseases involving the lung within 3 months before first dosing that may interfere with detection or management of drug-related pulmonary toxicity. Subjects who developed ≥Grade 3 ILD during prior immune checkpoint inhibitor treatment are excluded.
• Bowel obstruction within 3 months prior to first study treatment, or prior intestinal stent placement with the stent remaining in situ at screening.
• Uncontrolled or severe cardiovascular disease, or unstable angina/unstable arrhythmia occurring within 1 month before initiation of study treatment.
• Unexplained fever \>38.5°C at screening or prior to first dose; severe infection (CTCAE Grade \>2) within 4 weeks before study drug initiation; active pulmonary inflammation on baseline chest imaging, or clinical signs/symptoms of infection requiring oral or intravenous antibiotics within 2 weeks before first dosing.
• Previous or concurrent diagnosis of other malignant malignancies.
• History of immunodeficiency including positive HIV test, congenital/acquired immunodeficiency disorders, or prior solid organ transplantation.
• Active pulmonary tuberculosis infection within 1 year prior to screening, or prior active pulmonary tuberculosis without standard anti-tuberculosis treatment even if diagnosed more than 1 year ago.

Other illness

• Uncontrolled hypertension, or medical history of hypertensive crisis or hypertensive encephalopathy.
• History of severe cerebrovascular disease.
• Subjects with a history of or current leptomeningeal metastases, or active brain metastases.
• Active hepatitis B or active hepatitis C infection.
• Uncontrolled psychiatric disorders, known alcohol abuse, illicit drug dependence, incarceration or other conditions that would preclude completion of study procedures.

Lab values

• Any other conditions deemed inappropriate for study participation by the investigator, including clinically significant abnormal laboratory values, familial/social factors or other risks leading to premature study discontinuation or confounding study results.

Other

• Pre-existing peripheral neuropathy of Grade \>1.
• CT/MRI evidence of tumor encasement or invasion of major blood vessels.
• Symptomatic moderate to severe ascites; uncontrolled moderate or greater pleural or pericardial effusion.
• Pregnant, breastfeeding females or females planning pregnancy during the study period.

• Subjects voluntarily enroll in the study, sign informed consent, demonstrate good compliance and cooperate with follow-up visits.
• Aged between 18 and 75 years inclusive, male or female.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Estimated survival expectancy ≥ 12 weeks.
• Histologically or cytologically confirmed colorectal adenocarcinoma.
• No prior systemic anti-tumor therapy.
• Tumor tissue specimen must be provided, either archived within 1 year prior to first study treatment or newly collected fresh specimen.
• At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; the measurable lesion shall not have received prior local therapy such as radiotherapy.
• Adequate organ function with relevant laboratory tests completed within 7 days before the first study treatment.
• Male subjects with fertile female partners and fertile female subjects must use highly effective contraception throughout the study. Fertile female subjects must have a negative serum or urine human chorionic gonadotropin (HCG) test within 7 days prior to first study drug administration and shall not be breastfeeding.